• Bladder Cancer in the United States has
progressively been one of the more common
cancers and is estimated to have 74,000 new
cases as well as 16,000 deaths in 2015.1
• This type of cancer also has one of the highest
rates of recurrence with an average of 60%...
Canine transitional cell carcinoma (TCC) has been shown to have a substantial inflammatory component. It exhibits genotypic and morphologic elements that resemble its human counterpart. Cyclooxygenases (COX) are key enzymes in the synthesis of proinflammatory molecules, such as prostaglandins. Excess prostaglandin production through cyclooxygenases may promote oncogenesis and progression of...
Lymphoma (LSA) is one of the most common canine malignancies, and is almost invariably a terminal disease. Epigenetic changes in canine and human lymphomas have been linked to disease progression and poor prognosis, leading to the development of epigenetic-targeted therapies which have shown promise in treating various forms of human...
The serotonergic system plays a significant regulatory role in osteoblast differentiation and proliferation. Serotonin (five-hydroxytryptamine or 5HT) may promote or inhibit osteoblast proliferation depending upon the serotonin receptor isoforms expressed by the cell. Classically, 5HT receptor 1B (5HTR1B) reduces osteoblast proliferation by inhibiting phosphorylation of the cAMP response element binding...
Many humans and canines alike suffer from osteosarcoma, which is often metastatic, resistant to chemotherapy, and frequently fatal. The mechanisms through which osteosarcoma cells acquire resistance to chemotherapy are not entirely understood, and the role of exosomes as intercellular mediators of this resistance in osteosarcoma is unknown. Using established canine...
Canine Transitional Cell Carcinoma (TCC) makes up 2% of all canine cancers and is the most common cancer of the bladder for dogs. Usually diagnosed in its later stages, TCC is difficult to treat, with low survival times. Current diagnosis involves invasive techniques, and mainstream screening tests are often ineffective....
Background:
Osteosarcoma (OS) is an aggressive and often fatal cancer that afflicts over 1000 humans and 10,000 dogs per year in the United States. Recent evidence suggests deregulation in the signaling triad, receptor activator of nuclear factor kappa B (RANK), its activating ligand (RANKL), and the RANKL inhibitor, osteoprotegerin (OPG)...
Background
Bcl11b, previously CTIP2, is a zinc finger nuclear transcription factor involved in the development of keratinocytes, teeth, T lymphocytes, and nervous tissue. Expression of Bcl11b has been reported in human head and neck squamous cell carcinoma (HNSCC) and increased expression correlates with poorly differentiated tumors. This study aimed to...
Feline injection site sarcomas (FISS) are frequently encountered cutaneous and subcutaneous neoplasms of cats. Significant patient morbidity is related to the invasiveness these tumors display, typically requiring extensive local excision or amputation. As with many veterinary tumors, survival time and tumor recurrence for FISS is highly influenced by histologic margin...
Osteosarcoma (OSA) is the most common primary skeletal tumor in dogs accounting for 85% of bone tumors and nearly 6% of all canine neoplasms. They are highly aggressive tumors that carry a poor prognosis despite intensive treatment, highlighting the need for more effective diagnostic and therapeutic tools. Recent research in...